AP-203

N/A

Report date: 2023/10/17 16:51:14

Base Information

Drug NameAP-203
Drug Alias NameAP-203AP203
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 activatorsProgrammed death-ligand 1 blockers
TargetsTumor necrosis factor receptor superfamily member 9Programmed death-ligand 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAP Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAP Biosciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A